Taurine, an amino acid naturally present in the brain and in foods such as meat, fish, poultry and dairy, is drawing scientific attention for its possible role in protecting neurons and preserving memory. A review published in the journal Mammalian Genome looked at whether targeting taurine metabolism could help shield the nervous system from age-related neurodegenerative diseases. The authors come from Karolinska Institutet and St. Erik Eye Hospital in Sweden, working with researchers at the University of Pisa in Italy, King's College London and the Center for Eye Research Australia.
Taurine is found in all mammalian tissues and is especially concentrated in the brain and nervous system. According to the review, it helps guard cells against inflammation and oxidative stress, and it can dampen overactive nerve firing through interactions with inhibitory receptors. Animal studies have reported protective effects in models of epilepsy, stroke, neurodegeneration and diabetic neuropathy, and taurine supplementation has been linked to better cognitive performance in experimental models of cognitive impairment.
The evidence in Alzheimer's disease is suggestive but early. A small postmortem study found lower taurine levels in the temporal cortex of people with Alzheimer's compared with healthy controls. In transgenic mice, taurine supplementation reduced damage caused by amyloid-beta and improved cognition, and laboratory work suggests taurine can interfere with amyloid fibril formation. Patient-derived brain organoids treated with taurine showed less amyloid deposition and less accumulation of pathological tau. Similar animal-based findings are described for Parkinson's disease, ALS and Huntington's disease, while patient data in those conditions are more limited.
The review is also candid about the gaps. A meta-analysis of randomized controlled trials involving 402 participants found no significant cognitive benefit from taurine supplementation alone, and combination treatments showed improvements whose taurine-specific contribution remains unclear. Some earlier reports of declining circulating taurine with age were not borne out by newer longitudinal studies in humans, monkeys and mice. The authors note that doses used in animals cannot be directly translated to people, and they call for biomarker-guided clinical trials to identify who might benefit, when treatment should begin, and what role taurine actually plays in disease.